Table 5

 Summary of outcomes in studies of sibutramine

OutcomeNo of studies (sample size)Weighted mean difference or risk difference (active minus placebo) (95% CI)
Change in weight (kg)10 (2348)−4.16 (−4.73 to −3.59)
Change in weight (%)8 (1725)−4.34 (−5.01 to −3.67)
5% responders (absolute % difference)7 (1464)0.32* (0.27 to 0.37)
10% responders (absolute % difference)7 (1464)0.18* (0.11 to 0.25)
Change in:
 Waist circumference (cm)8 (1837)−3.99 (−4.70 to −3.28)
 BMI5 (956)−1.54 (−1.79 to −1.30)
 Weight in those with diabetes (%)3 (450)−4.99 (−3.78 to −6.20)
 Weight in those with diabetes (kg)3 (450)−4.91 (−3.64 to −6.18)
 Systolic blood pressure (mm Hg)7 (1906)1.69 (0.11 to 3.28)
 Diastolic blood pressure (mm Hg)7 (1906)2.42 (1.51 to 3.32)
 High density lipoprotein cholesterol (mmol/l)5 (977)0.04 (0.01 to 0.08)
 Triglycerides (mmol/l)4 (785)−0.18 (−0.30 to −0.07)
 Heart rate (beats/minute)7 (1658)4.53 (3.49 to 5.57)

*Risk difference. All other calculations represent weighted mean difference.